- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
BioCryst Pharmaceuticals is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.19 – a decrease of 4.01% over the previous week. BioCryst Pharmaceuticals employs 536 staff and has a trailing 12-month revenue of around $412.6 million.
Our top picks for where to buy BioCryst Pharmaceuticals stock
- Trade $0 commission stocks, ETFs, and options with as little as $1
- After-hours trading available
- Earn 4.5% interest on uninvested cash with Gold
- 24/7 customer support
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Complimentary access to a financial planner
How to buy BioCryst Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BCRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy BioCryst Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
BioCryst Pharmaceuticals stock price (NASDAQ: BCRX)
Use our graph to track the performance of BCRX stocks over time.BioCryst Pharmaceuticals shares at a glance
Latest market close | $7.19 |
---|---|
52-week range | $4.03 - $8.88 |
50-day moving average | $7.63 |
200-day moving average | $6.59 |
Wall St. target price | $14.64 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.61 |
Is it a good time to buy BioCryst Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioCryst Pharmaceuticals price performance over time
Historical closes compared with the close of $7.5 from 2024-11-29
1 week (2024-11-27) | 7.5 |
---|---|
1 month (2024-11-04) | 2.04% |
3 months (2024-09-04) | -9.42% |
6 months (2024-06-04) | 11.28% |
1 year (2023-12-04) | 21.16% |
---|---|
2 years (2022-12-02) | -41.36% |
3 years (2021-12-03) | 11.44 |
5 years (2019-12-04) | 165.96% |
BioCryst Pharmaceuticals financials
Revenue TTM | $412.6 million |
---|---|
Operating margin TTM | 6.57% |
Gross profit TTM | $10.9 million |
Return on assets TTM | -4.25% |
Return on equity TTM | -1925.37% |
Profit margin | -30.01% |
Book value | $-2.26 |
Market Capitalization | $1.6 billion |
TTM: trailing 12 months
BioCryst Pharmaceuticals share dividends
We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.
BioCryst Pharmaceuticals share price volatility
Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $4.03 up to $8.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 1.887. This would suggest that BioCryst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioCryst Pharmaceuticals overview
BioCryst Pharmaceuticals, Inc. , a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd. ; Seqirus UK Limited; Shionogi & Co.
Frequently asked questions
nullWhat percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?
Currently 1.148% of BioCryst Pharmaceuticals shares are held by insiders and 85.993% by institutions. How many people work for BioCryst Pharmaceuticals?
Latest data suggests 536 work at BioCryst Pharmaceuticals. When does the fiscal year end for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's fiscal year ends in December. Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703 What is BioCryst Pharmaceuticals's ISIN number?
BioCryst Pharmaceuticals's international securities identification number is: US09058V1035 What is BioCryst Pharmaceuticals's CUSIP number?
BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
9 Best Robo-Advisors for Automatic Investing
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Betterment alternatives
5 Betterment robo-advisor alternatives to consider when building your portfolio.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
-
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.
Ask a question